Mesoblast Limited (MESO)
(Delayed Data from NSDQ)
$8.48 USD
+0.10 (1.19%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $8.49 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Mesoblast Limited (MESO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.50 | $12.00 | $11.00 | 37.23% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Mesoblast Limited comes to $11.50. The forecasts range from a low of $11.00 to a high of $12.00. The average price target represents an increase of 37.23% from the last closing price of $8.38.
Analyst Price Targets (2 )
Broker Rating
Mesoblast Limited currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 1 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.50 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/24/2024 | Maxim Group | Michael Okunewitch | Hold | Strong Buy |
8/29/2024 | Not Identified | Not Identified | Hold | Strong Buy |
7/23/2024 | Piper Sandler | Edward A Tenthoff | Hold | Strong Buy |
6/4/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $11.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | NA |
MESO FAQs
Mesoblast Limited (MESO) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Mesoblast Limited (MESO) is $11.50. The current on short-term price targets is based on 2 reports.
The forecasts for Mesoblast Limited (MESO) range from a low of $11 to a high of $12. The average price target represents a increase of $35.61 from the last closing price of $8.48.
The current UPSIDE for Mesoblast Limited (MESO) is 35.61%
Based on short-term price targets offered by two analysts, the average price target for Mesoblast Limited comes to $11.50. The forecasts range from a low of $11.00 to a high of $12.00. The average price target represents an increase of 37.23% from the last closing price of $8.38.